In Brief: Genta
Executive Summary
Genta: Restructures operations to focus on near-term drug delivery development pipeline and "Anticode" cancer program, the San Diego-based company announces March 16. In reaction to constraints in the financial market and to reduce its burn rate, Genta has cut its research personnel by 25% since the beginning of 1995. The Anticode cancer program recently announced positive results in preclinical trials and will be moving into clinical trials in the U.K. in 1995. The company is pursuing corporate partners for development of dermatology products now in Phase II trials and for marketing Actagen, for which Genta will submit a marketing application in France this year...